SCHEMBL14719176

SCHEMBL14719176

FC(F)Oc1ccc(C#Cc2cc(OCc3ccccc3)c(OCc3ccccc3)nn2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 1/20 0.42
PPARG P37231 3/20 0.39
PPARA Q07869 3/20 0.39
PTPN1 P18031 1/20 0.37
PTPN6 P29350 1/20 0.37
PTPN11 Q06124 1/20 0.37
MAOB P27338 1/20 0.37
FFAR1 O14842 5/20 0.37
CSF1R P07333 1/20 0.36
ACACB O00763 2/20 0.35
FDFT1 P37268 1/20 0.35
LMNA P02545 3/20 0.35
MAPT P10636 1/20 0.35
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
POLB P06746 1/20 0.34
RAB9A P51151 1/20 0.34
KMT2A Q03164 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14719444 0.89 ACACB (0.41) MRGPRX4ACACB
SCHEMBL14719169 0.86 MAPT (0.40) PTPN1PTPN6PTPN11FFAR1ACACB
SCHEMBL14719454 0.86 L3MBTL1 (0.41) PTPN1PTPN6PTPN11MAPTSMN1; SMN2
SCHEMBL14719573 0.84 FFAR1 (0.47) MRGPRX4PTPN1PTPN6PTPN11MAOB
SCHEMBL14719672 0.82 MAOB (0.51) MRGPRX4MAOBPOLBALDH1A1
SCHEMBL14718339 0.82 CNR1 (0.41) LMNAMAPTMEN1NPC1RAB9A
SCHEMBL14719133 0.81 PTGER1 (0.38) MRGPRX4MAOBMAPTNPC1
SCHEMBL14729701 0.80 MEN1 (0.46) MRGPRX4PPARGPPARACSF1RLMNA
SCHEMBL14718770 0.80 PTGER1 (0.38) LMNAMAPTPOLBSMN1; SMN2HTT
SCHEMBL14718802 0.80 MRGPRX4 (0.40) MRGPRX4ACACBLMNAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12186313-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-01-07 US disclosed
US-20220008416-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-01-13 US disclosed
US-20220008416-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2022-01-13 US disclosed
US-11129828-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-09-28 US disclosed
US-11129828-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-09-28 US disclosed
US-20200121678-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICALS CO (JP) 2020-04-23 US disclosed
US-10463663-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-11-05 US disclosed
US-10463663-B2 Pyridazinone compounds and their use as DAAO inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2019-11-05 US disclosed
US-20180177780-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-06-28 US disclosed
US-20180177780-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2018-06-28 US disclosed
EP-2748149-B1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2015-10-21 EP disclosed
EP-2748149-B1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL (JP) 2015-10-21 EP disclosed
US-20150030704-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-01-29 US disclosed
US-20150030704-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-01-29 US disclosed
US-20150030704-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-01-29 US disclosed
EP-2748149-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2014-07-02 EP disclosed
WO-2013027000-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 WO disclosed
US-20130052281-A1 NOVEL COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 US disclosed
US-20130052281-A1 NOVEL COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 US disclosed
WO-2013027000-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130052281-A1 NOVEL COMPOUNDS ABCG2, F12, UGT1A1 MRGPRX4 97/4885PPARG 660/4885PPARA 1928/4885
US-20150030704-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD MRGPRX4 1286/4885PPARG 965/4885PPARA 1378/4885
US-12186313-B2 Pyridazinone compounds and their use as DAAO inhibitors PNPO, DAO, DPYD MRGPRX4 1286/4885PPARG 965/4885PPARA 1378/4885
US-20200121678-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD MRGPRX4 1286/4885PPARG 965/4885PPARA 1378/4885
US-11129828-B2 Pyridazinone compounds and their use as DAAO inhibitors PNPO, DAO, DPYD MRGPRX4 1286/4885PPARG 965/4885PPARA 1378/4885
US-20180177780-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD MRGPRX4 1286/4885PPARG 965/4885PPARA 1378/4885
US-10463663-B2 Pyridazinone compounds and their use as DAAO inhibitors PNPO, DAO, DPYD MRGPRX4 1286/4885PPARG 965/4885PPARA 1378/4885
US-20220008416-A1 PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS PNPO, DAO, DPYD MRGPRX4 1286/4885PPARG 965/4885PPARA 1378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.